Who is John Adlesich and some of his public health thoughts

John Adlesich or the ascent of a healthcare manager professional on healthcare industry trends in 2021: Deeper relationships and back-up suppliers. The value of vendor-of-choice relationships became apparent as many hospitals scrambled for pandemic-related supplies. The key is striking a strategic balance between price, performance and trust. Getting the lowest price but lacking a relationship that cannot be “prioritized” in a crisis is not ideal. Neither is overreliance on one vendor without having plans B, C and D in place. We see many organizations developing connections with tiers of back-up suppliers — often smaller and geographically closer than their primary vendors — to gain flexibility, speed and as much certainty as possible that critical items will be on hand when needed.

John Adlesich about behavior therapy in 2021: Applied Behavioral Analysis is a highly effective method for mediating behavior across a variety of domains. The technique relies on the observation and analysis of the antecedents (A) of the targeted behavior (B) and the resultant consequence (C) of that behavior. Antecedents are sometimes referred to as triggers and are the first step in identifying the cause of a challenging or undesirable behavior. This ABC methodology provides a foundation for clinicians to develop a highly specific and thorough treatment plan. Professionals will use this observed data, along with information provided by caregivers and loved ones, to develop a plan specific to your child’s needs.

John Adlesich about healthcare industry trends: Democratic control in the Senate will also impact healthcare. For example, Washington state Senator Patty Murray will chair the Senate Committee on Health, Education, Labor, and Pensions. She has advocated for a more robust federal response on COVID-19. And Senator Ron Wyden, Oregon, leads the Finance Committee and has pushed for drug pricing reform and drug price negotiation. These appointments and nominations point to a strong emphasis on COVID-19 recovery and vaccine distribution and coordination. For example, Fauci remains as the Director of the National Institute of Allergies and Infectious Diseases, and there’s now a COVID-19 data director (Shahpar), indicating this administration will emphasize data and reporting. Also evident in these appointments is a Biden administration focus on health equity and healthcare disparities—particularly with Nunez-Smith as the first Equity Task Force Chair for COVID-19. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.

John Adlesich thinks that 2021 is an important year for the healthcare industry. History gives us many reasons to doubt predictions. In 1916, Charlie Chaplin famously called the motion pictures “a fad.” In 1932, Albert Einstein said that nuclear power was not possible. In 2008, Steve Ballmer predicted the iPhone would be a flop. As these cases show, smart people may see the facts, but not the environmental factors that can shift the entire landscape. This was particularly true in 2020, a year that redefined “normal” and altered our world in ways we are only beginning to understand. In this environment, the hard job of accurately predicting future trends became that much more difficult. When I look back at my own predictions last year, almost none of them played out as I thought due to the pandemic and the complete upending of the national health care agenda. But now 10 months in, the pandemic’s true impact is starting to be understood. For 2021, job number one for the nation will be moving ahead with the largest mass vaccination program in our history, as well as improving our rapid testing capabilities and therapeutic treatments for COVID-19, in order to build our herd immunity and allow us to safely reopen and repair our badly damaged economy. This backdrop will permeate all our decisions this year, and directional trends will largely be influenced by how quickly we make progress in these areas.